se of Procalcitonin in therapy of Pneumonia

Not Applicable

• Conditions: Condition 1: Chronic obstructive pulmonary disease. Condition 2: Pneumonia.; Chronic obstructive pulmonary disease with acute exacerbation, unspecified; Pneumonia, unspecified

• Registration Number: IRCT2017010331737N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Patients to be at least 18 years; with diagnosis of Community Acquired Pneumonia ( CAP ) or Chronic Obstructive Pulmonary Disease ( COPD ) exacerbation; with at least one respiratory symptom ( cough, sputum, dyspnea, tachypnea, pleuretic chest pain ); in addition to at least one respiratory sign on auscultation (rales,cripitation); or one infection indicator ( T greater than 38 c, chills, WBC less than 4000 or greater than 10000 per milliliter ); hospitalized in Infectious ward of Arak Valiasr University Hospital.
Exclusion criteria:
Patients that can't consent voluntary; active IV drug users; severe immunosuppression ( except use of corticosteroid ); severe comorbidity; patients with hospital- acquired pneumonia ( pneumonia presented at 48 hours after hospitalization or previous history of hospitalization during 14 days before this admission ); patients requiring antibiotic therapy for chronic infection.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: 14 days after intervention. Method of measurement: day.;Duration of treatment. Timepoint: 14 days after intervention. Method of measurement: day.

Secondary Outcome Measures

Name	Time	Method
Clinical Results. Timepoint: 3, 5, 7, 14 days after intervention. Method of measurement: Clinical assessment.